The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 13 September 2012 up to and including 19 September 2012 the Company bought 550 own shares representing 0.00042% of the share capital of the Company, to the total value of BGN 1330.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.418.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of Sopharma AD (the “Company”) presents the Invitation and the materials for the Extraordinary General Meeting of shareholders of "Sopharma” AD, which shall take place on 1 November 2012 from 11.00 AM and, in the absence of a quorum - on 15 November 2012 from 11.00 AM in Sofia, "Iliensko shosee" No 16.
Attachments:
1.Invitation to EGM;
2.Minutes of the meeting of the Board of Directors for the convening of EGM
3.Sample letter of attorney for EGM
The Board of Directors of Sopharma AD (the “Company”) hereby notifies that the Invitation to the Extraordinary Meeting of Shareholders of “Sopharma” AD, which will take place on 1 November 2012 at 11:00, and in the absence of a quorum – on 15 November 2012 at 11:00 in Sofia, 16 “Iliensko shose” Str., has been registered in the Commercial Register under number 20120925101646.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 20 September 2012 up to and including 26 September 2012 the Company bought 400 own shares representing 0.0003% of the share capital of the Company, to the total value of BGN 963.80 on the Bulgarian Stock Exchange. The average price per share was BGN 2.41.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 27 September 2012 up to and including 3 October 2012 the Company bought 600 own shares representing 0.00045% of the share capital of the Company, to the total value of BGN 1445.4 on the Bulgarian Stock Exchange. The average price per share was BGN 2.41.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of Sopharma AD (the “Company”) notifies that for September 2012 sales revenues remained at the same level compared to the same period of 2011, including 9% decrease of domestic sales and 4% increase of export sales.
During the first nine months of this year Sopharma AD realized an increase of sales revenues of 2%, including 10% decrease of domestic sales and 7% increase of export sales compared to the same period of 2011.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 4 October 2012 up to and including 10 October 2012 the Company bought 1020 own shares representing 0.00077% of the share capital of the Company, to the total value of BGN 2432.6 on the Bulgarian Stock Exchange. The average price per share was BGN 2.38.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 11 October 2012 up to and including 17 October 2012 the Company bought 1100 own shares representing 0.00083% of the share capital of the Company, to the total value of BGN 2640.00 on the Bulgarian Stock Exchange. The average price per share was BGN 2.40.
The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.
The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 18 October 2012 up to and including 24 October 2012 the Company bought 1100 own shares representing 0.00083% of the share capital of the Company, to the total value of BGN 2610.70 on the Bulgarian Stock Exchange. The average price per share was BGN 2.37.
The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers.
The Board of Directors of Sopharma AD (the “Company”) hereby notifies that on 29 October 2012 was signed a merger agreement between Sopharma AD and Bulgarian Rose – Sevtopolis AD. The agreement settles both the technical process of the merger of Bulgarian Rose – Sevtopolis AD into Sopharma AD, as well as the ensuing consequences for the two companies. The contract and the accompanying documentation have been submitted to the Financial Supervision Commission.
